Johnson & Johnson (JNJ.US) reported fourth-quarter results that surpassed analyst expectations. The company posted sales of $21.40 billion and net income of $4.13 billion for the fourth quarter of 2023. On a per-share basis, net earnings were $1.70 compared to $1.22 in the same quarter a year ago when net income was $3.23 billion. Excluding one-time items, the company’s adjusted earnings per share amounted to $2.29 for the most recent quarter.
Following the spinoff of its former consumer products division, Kenvue, Johnson & Johnson now operates through two business segments: Innovative Medicine, comprised of its pharmaceuticals division, and MedTech, representing its medical devices. Innovative Medicine revenue grew 4.2% to $13.7 billion during the quarter, while MedTech sales surged 13.3% to $7.7 billion.
J&J progressed in obtaining approvals for several new treatments, including its Balversa drug for bladder cancer. However, the company’s lucrative Stelara medication faces mounting competition in Europe as early as mid-2024. During an investor call, CEO Joaquin Duato stated that J&J is pursuing acquisitions and is open to considering “many types of deals.”
Johnson & Johnson’s full-year 2024 guidance is unchanged from its December forecasts. The company projects operational sales growth of 5-6%, amounting to $88.2-$89 billion. For earnings, J&J forecasts adjusted EPS of $10.55-$10.75, reflecting a 6.4-8.4% increase over last year. This EPS guidance aligns with the Wall Street consensus of $10.68.
(Johnson & Johnson Stock Performance Monthly Chart)
Disclaimer
Comments, news, research, analysis, price, and all information contained in the article only serve as general information for readers and do not suggest any advice. Ultima Markets has taken reasonable measures to provide up-to-date information, but cannot guarantee accuracy, and may modify without notice. Ultima Markets will not be responsible for any loss incurred due to the application of the information provided.
